Adaptive Biotechnologies Corpor (ADPT) Stock Price & How to Invest

Adaptive Biotechnologies (NASDAQ: ADPT) runs an immune-medicine platform built around reading the genetics of the adaptive immune system. Its commercial engine is clonoSEQ, an FDA-cleared minimal residual disease (MRD) test that measures how many cancer cells remain in a patient during and after treatment, used mainly in blood cancers such as multiple myeloma, ALL, and CLL. The MRD segment now contributes roughly 95 percent of revenue and includes both clinical testing and pharma partnerships that use the platform in drug trials. A second Immune Medicine arm pursues drug discovery and includes a long-running collaboration with Genentech on neoantigen-directed T-cell therapies.

The investment picture is a diagnostics growth story reaching an inflection point. First-quarter 2026 revenue rose about 35 percent year over year to roughly $70.9 million, MRD revenue grew about 53 percent, and clonoSEQ test volume climbed about 41 percent, prompting management to raise full-year MRD guidance toward roughly $260 million to $270 million. Losses have narrowed sharply and adjusted EBITDA is near breakeven, while a large cash balance funds the runway. In June 2026 the company announced a plan to separate the profitable, scaled MRD business from the earlier-stage Immune Medicine unit, a move that could reshape how the two pieces are valued.

ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. The MRD diagnostics market is competitive, with Natera, Guardant Health, Exact Sciences, and NeoGenomics all pushing MRD and liquid-biopsy offerings, and reimbursement decisions can swing revenue. Pharma milestone revenue is lumpy and hard to forecast quarter to quarter. The announced business separation adds execution and structural uncertainty, and the Immune Medicine drug programs, including the Genentech-linked work, are early stage with binary outcomes. The stock has also been volatile, trading across a wide 52-week range.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Adaptive Biotechnologies Corpor's investor relations page or your broker.

• Revenue (TTM): ~$250M
• Q1 2026 revenue: ~$70.9M (up ~35% YoY)
• 2026 MRD revenue guidance: ~$260M to $270M
• Q1 2026 net loss: ~$20M (improved from ~$30M)
• Cash and investments: ~$237M
• Market cap: ~$3.6B

As of July 2026 ADPT trades at a high revenue multiple typical of a growing, near-breakeven diagnostics company rather than on earnings, since it remains unprofitable on a consolidated basis. The large cash balance relative to burn gives multi-year runway. Valuation hinges heavily on continued MRD volume growth and how the market treats a potential separation.

There are three common ways to get ADPT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ADPT sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ADPT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

ADPT is a scaling MRD diagnostics business inside a still-unprofitable immune-medicine shell, with a planned split that could sharpen the investment case in either direction.

Whether ADPT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ADPT a buy?, and where the stock could go from here in the ADPT stock forecast.

For income investors, whether ADPT pays a dividend and how the payout looks is covered in does ADPT pay a dividend?